Core Insights - Understanding the molecular drivers of the transition from precancerous lesions to malignant tumors is crucial for early cancer detection and intervention [2] - The study published in Cancer Cell reveals the molecular mechanisms underlying the early malignant transition of hepatocellular carcinoma (HCC) [2] Group 1: Importance of Early Detection - The transition from precancerous nodules to early cancer is a critical stage in cancer formation, necessitating monitoring and immediate medical intervention upon diagnosis of malignancy [4] - Previous studies using unrelated precancerous samples have made statistical inferences about changes during malignant transformation, but many precancerous lesions may not progress to cancer [4] Group 2: Research Findings - The study analyzed 21 very early hepatocellular carcinoma (veHCC) cases within 17 dysplastic nodules (DN), revealing that 82% of these DN exhibited TERT gene mutations, indicating a predisposing risk factor for malignant transformation [6][9] - Accumulation of copy number variations (CNA), rather than single nucleotide mutations, was significantly associated with malignant transformation [6] - The findings suggest two evolutionary pathways for early malignant transition in liver cancer: a CNA-dominated progression pathway and an inflammatory progression pathway associated with early immune evasion [7]

Core Viewpoint - Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by the absence of estrogen receptors, progesterone receptors, and HER2 expression. Recent studies indicate that sensory neurons play a significant role in the tumor microenvironment (TME) of TNBC, contributing to immune exclusion and tumor progression [2][4][15]. Group 1: Role of Sensory Neurons in TNBC - Sensory neurons are identified as the dominant neuron type in the TNBC ecosystem, comprising approximately 70% of the nerve fiber area in TNBC tissues, significantly higher than sympathetic and parasympathetic neurons [7]. - Patients with positive perineural invasion (PNI) exhibit worse prognoses, including higher rates of lymph node and bone metastases, alongside reduced immune cell infiltration and increased collagen deposition in the TME [7]. Group 2: Mechanism of Immune Exclusion - The study outlines a clear signaling pathway where tumor cells secrete nerve growth factor (NGF) to attract sensory neurons, which then release the neuropeptide CGRP, activating cancer-associated fibroblasts (CAFs) [9]. - The CGRP-RAMP1 signaling axis promotes the transformation of CAFs into myofibroblasts, leading to significant collagen deposition that physically obstructs immune cell infiltration [9]. Group 3: Therapeutic Strategies - Targeting the CGRP-RAMP1 signaling axis with the FDA-approved migraine medication Rimegepant shows promise in TNBC treatment, as it significantly inhibits tumor growth, reduces collagen deposition, and enhances the infiltration of immune cells like CD8+ T cells [10][13]. - Clinical data suggest that high CGRP expression correlates with poorer prognosis and reduced response to immunotherapy, indicating its potential as a biomarker for selecting patients who may benefit from combination therapies [13]. Group 4: Conclusion and Future Directions - The findings reveal that sensory neurons are not mere bystanders but active participants in tumor progression by facilitating immune evasion in TNBC [15]. - The research opens new avenues for cancer neurobiology, emphasizing the need for multi-faceted approaches that target both cancer cells and their surrounding ecosystems [16].

Core Viewpoint - The study reveals the dual role of intratumoral bacteria in regulating tumor immunity, highlighting the significant impact of bacterial invasion on immune responses and tumor recurrence [3][12][18]. Group 1: Tumor Microenvironment and Immune Response - Tumors are categorized as "hot" (immune-activated) or "cold" (immune-suppressive) based on immune cell infiltration and activity, with cold tumors showing insufficient immune response and resistance to immunotherapy [2]. - The presence of intratumoral bacteria is linked to regional immune-suppressive microenvironments, influencing cancer cell behavior and immune cell function through various mechanisms [2][3]. Group 2: Research Findings on Bacteria and Tumor Cells - The research conducted by Cai Shang's team demonstrates that intracellular bacteria activate the cGAS-STING-IL17B signaling pathway in cancer cells, leading to the induction of neutrophils into an immune-suppressive state, thus promoting tumor recurrence [3][12]. - In contrast, extracellular bacteria induce neutrophil subpopulations with anti-tumor functions, activating immune responses that inhibit tumor recurrence [3][12]. Group 3: Methodology and Experimental Models - A strict model for studying intracellular bacteria was established using organoid-bacteria co-culture systems, allowing for the specific investigation of the physiological functions of intracellular bacteria [8]. - In preclinical mouse models, the presence of intracellular bacteria was found to be a key factor in long-term tumor recurrence, with antibiotic treatment reducing recurrence rates significantly from 65% to 6.7% [9]. Group 4: Immune Cell Dynamics - Single-cell RNA sequencing revealed that intracellular bacteria induce neutrophils with myeloid-derived suppressor cell (G-MDSC) characteristics, while extracellular bacteria promote neutrophils with anti-tumor profiles [11][12]. - The cGAS-STING pathway is crucial for the immune reprogramming induced by bacterial invasion, with IL-17B identified as a key mediator in promoting immune suppression [12][14]. Group 5: Clinical Relevance and Future Directions - The study indicates that the strength of bacterial signals within tumor tissues correlates positively with neutrophil infiltration and is associated with poorer prognosis in breast cancer patients [15][19]. - Future research aims to explore targeted strategies for eliminating or limiting intracellular bacterial invasion, optimizing postoperative antibiotic and immunotherapy combinations to prevent tumor recurrence [19].

Core Viewpoint - The article discusses the complex interactions between cancer cells and the tumor microenvironment (TME), emphasizing the potential of targeted cancer immunotherapies to disrupt immunosuppressive interactions, although many therapies show limited durability due to a lack of understanding of these interactions [2][3]. Group 1: Research Findings - A study published by a team from the University of Chicago reveals that tumor-initiating stem cells (tSC) regulate the plasticity of neutrophils through metabolic reprogramming, creating a protective niche that allows them to survive cancer immunotherapy, leading to cancer recurrence [4]. - The research indicates that targeting the SOX2-FADS1-PGE2 signaling axis could serve as a novel combination therapy strategy to prevent immunotherapy resistance and tumor recurrence [4]. Group 2: Mechanisms of Immune Evasion - The study highlights the heterogeneity of tumor-associated neutrophils (TAN) and how different states of TAN arise and evolve, impacting the effectiveness of cancer immunotherapy [8]. - It was found that anti-PDL1 + CD40 agonist immunotherapy can induce TAN to regain anti-tumor activity in squamous cell carcinoma (SCC), while TAN at the tumor-stroma interface maintain their immunosuppressive state [8]. Group 3: Key Pathways and Implications - The SOX2 high-expressing tSCs enhance PGE2 signaling in TAN, which may disrupt interferon responses and inhibit the anti-tumor functions of TAN [9]. - Specific knockout of PGE2 receptors in neutrophils or using COX-2 inhibitors to block PGE2 synthesis can effectively restore the anti-tumor functions of neutrophils, enhancing the efficacy of immunotherapy and significantly reducing tumor recurrence rates [9]. Group 4: Overall Conclusions - The research explores how effective immunotherapies influence the plasticity of TAN, revealing how tSCs evade TAN-mediated anti-tumor immunity, allowing them to survive cancer immunotherapy and promote recurrence [12].

Core Viewpoint - The study highlights the role of Cathepsin-D (CTSD) in immune evasion in microsatellite stable colorectal cancer (MSS CRC), suggesting that targeting CTSD can enhance the efficacy of anti-PD-1 therapies [2][3][5]. Group 1: Research Findings - CTSD is overexpressed in colorectal cancer, leading to immune evasion and treatment resistance [7]. - CTSD promotes the degradation of MHC-I through the lysosomal pathway, which hinders its recycling to the cell surface [5][7]. - Gene knockout or pharmacological inhibition of CTSD can block immune evasion and enhance the efficacy of anti-PD-1 therapy [6][9]. Group 2: Implications for Treatment - Targeting CTSD in conjunction with anti-PD-1 immunotherapy could potentially improve treatment outcomes for patients with MSS CRC [8][9].

Core Viewpoint - The article discusses the challenges and advancements in immunotherapy for pancreatic ductal adenocarcinoma (PDAC), highlighting a recent phase 1/2 clinical trial that demonstrates the safety and feasibility of autologous multiantigen-targeted T cell therapy for PDAC patients [2][3]. Summary by Sections Immunotherapy Challenges - PDAC presents significant challenges for effective immunotherapy due to weak expression of target antigens and frequent upregulation of immunosuppressive molecules, leading to a "cold tumor" microenvironment [2]. - The heterogeneity of tumor antigen expression can result in rapid adaptation and modulation of target antigens, hindering the potential of T cell monotherapy [2]. Clinical Trial Overview - A phase 1/2 clinical trial named TACTOPS was conducted to evaluate the safety and feasibility of an autologous non-engineered T cell product administered monthly at a dose of 1×10^7 cells/m² [7]. - The trial included three arms: patients responsive to first-line chemotherapy (Group A, n=13), patients resistant to first-line chemotherapy (Group B, n=12), and patients with resectable disease (Group C, n=12) [7]. Trial Results - Among 56 participants, 37 received the infusion with only one treatment-related serious adverse event reported [8]. - Disease control rates were 84.6% for Group A and 25% for Group B, while 2 out of 9 patients in Group C remained disease-free after 66 months of follow-up [8]. - The infused cells persisted for 12 months post-treatment, with responders showing higher levels of tumor-directed T cells compared to non-responders [8]. Conclusion and Future Directions - The study confirms the feasibility of generating autologous multi-tumor-associated antigen (mTAA) T cells for patients at all stages of pancreatic cancer, with a maximum of six infusions at a dose of 1×10^7 cells/m² being safe [8]. - The clinical outcomes are associated with the peripheral expansion of mTAA-targeted T cell clones and the emergence of antigen spreading during treatment, suggesting further research into TAA T cells as a standalone therapy or in combination with other novel immunotherapies or standard treatments [8].

Core Viewpoint - The study identifies RNA-binding proteins (RBPs) as key regulators of immune evasion in high-grade serous ovarian cancer (C5-HGSC), suggesting that inhibiting IGF2BP1 can enhance the efficacy of PD-1 blockade therapy [2][4][6]. Group 1: Research Findings - The research integrates single-cell RNA sequencing with bulk RNA sequencing data, marking the first discovery that RBPs are critical for immune evasion in C5-HGSC [4]. - IGF2BP1 is confirmed as a core mediator of immune evasion in both in vitro and in vivo models, functioning by accelerating the degradation of IRF1 protein to block gamma-interferon signaling and inhibit MHC-I antigen presentation [4]. - The study reveals that IGF2BP1 dissociates the relationship between PD-L1 expression and IRF1-dependent transcription, thereby limiting immune cell infiltration and T cell activation [4]. Group 2: Therapeutic Implications - The small molecule compound BTYNB effectively inhibits IGF2BP1 and can work synergistically with PD-1 blockade to reverse immune evasion in vivo [4]. - The findings are validated using multispectral imaging technology in human HGSC tissue samples, highlighting the role of cancer embryonic RBPs as molecular drivers of the C5-HGSC subtype [4][6].

Core Insights - The recent increase in COVID-19 positivity rates indicates a small peak, with notable cases leading to event cancellations, such as singer Eason Chan's concert postponement [1][2] Summary by Sections Current COVID-19 Situation - The positivity rate for COVID-19 has risen from 7.5% to 16.2% in outpatient flu-like cases and from 3.3% to 6.3% in hospitalized severe acute respiratory infection cases during the monitoring period from March 31 to May 4 [2] - Experts warn that the current wave is a small peak, with predictions that the positivity rate will decline to 8%-10% by early June and below 5% by mid to late June [5] Vulnerable Populations - Elderly individuals remain a high-risk group, with the highest positivity rates observed in those aged 60 and above during the recent monitoring period [3] - Immunocompromised individuals and those with chronic conditions are particularly at risk for severe outcomes [3][4] Virus Characteristics - The current circulating strain is primarily the NB.1 series, which shows no significant change in pathogenicity compared to previous strains, although it has a higher transmission advantage [6] - The NB.1 strain exhibits greater immune evasion capabilities but is not expected to cause more severe disease than previous variants [6] Regional Variations - Southern provinces have reported slightly higher COVID-19 positivity rates compared to northern provinces, attributed to climatic differences that favor virus transmission [7]